<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Protamine: Administration and management of adverse reactions during cardiovascular procedures
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Protamine: Administration and management of adverse reactions during cardiovascular procedures
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Protamine: Administration and management of adverse reactions during cardiovascular procedures
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jerrold H Levy, MD, FAHA, FCCM
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kamrouz Ghadimi, MD, MHSc, FAHA
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jonathan B Mark, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nancy A Nussmeier, MD, FAHA
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Feb 28, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2962676259">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9831" href="/z/d/drug information/9831.html" rel="external">
          Protamine sulfate
         </a>
         is routinely administered to reverse the systemic anticoagulation effects of
         <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">
          unfractionated heparin
         </a>
         (UFH) after cardiac surgery or surgical and percutaneous vascular procedures. There are no alternative agents to reverse UFH.
        </p>
        <p>
         This topic will discuss protamine administration and dosing, as well as recognition, treatment, and prevention of adverse reactions to protamine.
        </p>
        <p>
         Reversal of heparin anticoagulation with protamine in nonsurgical patients with heparin-associated bleeding is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">
          "Heparin and LMW heparin: Dosing and adverse effects", section on 'Bleeding'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1325.html" rel="external">
          "Reversal of anticoagulation in intracranial hemorrhage", section on 'Protamine sulfate'
         </a>
         .)
        </p>
        <p>
         A separate topic discusses detailed management of a perioperative anaphylactic reaction to any agent. (See
         <a class="medical medical_review" href="/z/d/html/2077.html" rel="external">
          "Perioperative anaphylaxis: Clinical manifestations, etiology, and management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2779596983">
         <span class="h1">
          PROTAMINE REVERSAL OF HEPARIN ANTICOAGULATON: USES AND DOSING STRATEGIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intravenously administered
         <a class="drug drug_general" data-topicid="9831" href="/z/d/drug information/9831.html" rel="external">
          protamine sulfate
         </a>
         rapidly binds to
         <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">
          unfractionated heparin
         </a>
         (UFH) to reverse its effect, with a half-life of approximately five minutes after IV administration [
         <a href="#rid1">
          1
         </a>
         ]. Protamine dosing strategies depend on the heparin dose administered and the specific setting (eg, cardiovascular surgery with cardiopulmonary bypass [CPB] or cardiovascular interventions without CPB).
        </p>
        <p class="headingAnchor" id="H1614485430">
         <span class="h2">
          Protamine administration after cardiopulmonary bypass
         </span>
        </p>
        <p class="headingAnchor" id="H3114457200">
         <span class="h3">
          General considerations
         </span>
         <span class="headingEndMark">
          —
         </span>
         General considerations for reversal of anticoagulation with protamine after CPB include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neutralizing heparin at the end of CPB
         </strong>
         –
         <strong>
         </strong>
         High heparin concentrations are present immediately after weaning from CPB in patients undergoing cardiac surgery. Systemic anticoagulation with heparin is maintained at a higher level during CPB compared with other procedures or medical conditions in which heparin is used. The degree of heparin anticoagulation is monitored throughout CPB, using a point-of-care (POC) contact activation test of the effects of heparin, the activated clotting time (ACT). ACT values are measured approximately every 30 minutes, and additional heparin is administered as necessary to achieve and maintain a targeted value (typically &gt;480 seconds). ACT values of 400 to 480 seconds correlate with blood levels of heparin of approximately 4 to 6 units/mL [
         <a href="#rid2">
          2-4
         </a>
         ]. However, the relationship between ACT values and blood levels of UFH is not linear and is often inconsistent during CPB, after separation from CPB, and following protamine administration to reverse anticoagulation [
         <a href="#rid4">
          4-6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Details regarding heparin administration and maintenance of heparin anticoagulation throughout CPB are discussed in separate topics. (See
         <a class="medical medical_review" href="/z/d/html/94297.html" rel="external">
          "Blood management and anticoagulation for cardiopulmonary bypass", section on 'Heparin administration and monitoring'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/103812.html" rel="external">
          "Management of cardiopulmonary bypass", section on 'Maintenance of anticoagulation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Timing of protamine administration
         </strong>
         –
         <strong>
         </strong>
         Administration of protamine to neutralize heparin is typically initiated after weaning from CPB and completed following successful aortic decannulation. Exact timing of administration (before or after aortic decannulation) varies according to institutional and surgical preferences. (See
         <a class="local">
          'Timing of administration'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Notably, use of cardiotomy suction (ie, the “pump sucker”) to suction blood from the surgical field into the CPB reservoir is discontinued either at the onset of protamine administration or when a small portion (typically less than one-third) of the total initial dose has been administered. Conceptually, this avoids neutralization of heparin and clot formation in the blood remaining in the CPB reservoir, which would prohibit emergency reinstitution of CPB.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3955805257">
         <span class="h3">
          Initial protamine dosing strategies
         </span>
         <span class="headingEndMark">
          —
         </span>
         We agree with professional society recommendations noting that optimal reversal of systemic anticoagulation after CPB is based on stoichiometric measurements of currently circulating heparin levels, using a POC heparin-protamine titration assay, if available [
         <a href="#rid7">
          7-12
         </a>
         ]. Such assays facilitate appropriate protamine dosing to neutralize residual heparin, while avoiding excess protamine administration.
        </p>
        <p>
         Professional society recommendations also note that if empiric dosing of protamine is used (eg, because a POC heparin-protamine titration assay is not available), this should be based on a protamine-to-heparin ratio that does not exceed 1 mg of protamine for every 100 units of previously administered heparin [
         <a href="#rid7">
          7-12
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4150521532">
         <span class="h4">
          Titration based on point-of-care heparin assays
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several POC heparin-protamine titration assay systems are commercially available and used in cardiac surgical patients to determine the residual circulating heparin level based on incremental dosing of protamine in the cartridge (eg, Hepcon/HMS
         <sup>
          ®
         </sup>
         , Hemochron RxDx, or other protamine-dose assays). These devices measure the residual heparin concentration at the end of CPB to automatically calculate a precise dose of protamine [
         <a href="#rid4">
          4
         </a>
         ]. At the completion of protamine administration, the presence of any residual heparin can be determined using such devices to calculate any additional dose of protamine that may be needed. (See
         <a class="local">
          'Dosing for continued bleeding after initial protamine administration'
         </a>
         below and
         <a class="local">
          'Avoiding heparin rebound'
         </a>
         below.)
        </p>
        <p>
         A 2013 meta-analysis of four randomized trials in 507 cardiac surgical patients noted that use of a heparin-protamine titration assay resulted in significantly less postoperative blood loss (range 625 to 839 mL) compared with use of fixed empiric protamine dosing methods (range 765 to 995 mL) [
         <a href="#rid13">
          13
         </a>
         ]. Furthermore, overall transfusion of red blood cells (RBCs) was less in the assay group (0.2 to 1.8 units) compared with the fixed dose group (0.3 to 2.7 units) [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
         However, heparin-protamine titration assay systems are expensive and are not available in every institution. Furthermore, institutions with only one or two systems may reserve their use for more complex high-risk cardiac surgical procedures.
        </p>
        <p class="headingAnchor" id="H1035014899">
         <span class="h4">
          Empiric dosing strategies
         </span>
         <span class="headingEndMark">
          —
         </span>
         If a POC heparin-protamine titration assay is not available, most centers employ an empiric (fixed dose) strategy, basing a calculated protamine dose on the amount of heparin that had been administered. Although ACT values are measured in an attempt to determine adequacy of anticoagulation reversal, the correlation of ACT values and blood levels of UFH is neither linear nor consistent [
         <a href="#rid4">
          4-6
         </a>
         ].
        </p>
        <p>
         A classic empiric dosing strategy used a calculation of 1 mg of protamine for every 100 units of heparin administered (ie, a 1:1 ratio). In some centers, the calculated protamine dose included the heparin used to prime the extracorporeal circuit, as well as any additional doses of heparin that were administered during CPB [
         <a href="#rid4">
          4
         </a>
         ]. Empiric dosing strategies do not take into account heparin metabolism or consumption by the extracorporeal circuit; thus, an excessive dose of protamine may be administered. This increases the risk for coagulopathy due to the adverse anticoagulant effects of protamine. Exacerbated coagulopathy due to excess protamine administration is particularly likely when the protamine-to-heparin dosing ratio exceeds 1.3:1 [
         <a href="#rid14">
          14-16
         </a>
         ].
        </p>
        <p>
         For these reasons, we suggest modifications of this classic empiric dosing strategy that may minimize risk of administering excess protamine. Examples include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Using a lower dosing ratio of protamine-to-heparin that is less than 1:1 in calculations of the empiric dose.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         This strategy may reduce transfusions. One randomized trial in 96 cardiac surgical patients compared use of a lower ratio of 0.8:1 with use of a higher ratio of 1.3:1 of protamine to heparin [
         <a href="#rid15">
          15
         </a>
         ]. Post-reversal ACT values were similar in both protamine dosing groups. However, significantly less 24-hour postoperative chest tube drainage (470 versus 615 mL) and decreased incidences of transfusion of fresh frozen plasma (0 versus 11 percent) and platelet concentrates (6 versus 21 percent) were noted in the lower ratio group. In addition, higher values for thrombin generation (a measure of adequacy of clot formation) were noted in the lower ratio group (38 ± 40 versus 6 ± 9 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Limiting the protamine dose calculation by using only the initial heparin dose administered with or without including the heparin dose used to prime the CPB circuit.
        </p>
        <p>
        </p>
        <p>
         We do not use empiric dosing strategies that are based on the total amount of heparin administered throughout the duration of CPB. Also, we do not use older empiric dosing methods that were based on body weight.
        </p>
        <p class="headingAnchor" id="H3910864089">
         <span class="h4">
          Pharmacokinetic dosing to avoid excess protamine
         </span>
         <span class="headingEndMark">
          —
         </span>
         Protamine dosing algorithms based on pharmacokinetics of heparin have been developed to consider all heparin doses and timing in calculating a protamine dose [
         <a href="#rid16">
          16
         </a>
         ]. The goal is to improve reversal of anticoagulation, while avoiding excess protamine after CPB.
        </p>
        <p>
         In one randomized trial conducted in 40 cardiac surgical patients, calculation of protamine doses using a pharmacokinetic-based algorithm was compared with use of the institution’s traditional heparin and protamine dosing strategy based on body weight [
         <a href="#rid17">
          17
         </a>
         ]. Patients in the pharmacokinetic algorithm group received lower protamine doses (211 ± 56 versus 330 ± 61 mg) and had a lower protamine-to-heparin ratio (0.49 versus 0.81), as well as less postoperative bleeding (480 versus 694 mL). However, such pharmacokinetic dosing strategies are not pragmatic in the operating room setting.
        </p>
        <p class="headingAnchor" id="H776988973">
         <span class="h3">
          Dosing for continued bleeding after initial protamine administration
         </span>
         <span class="headingEndMark">
          —
         </span>
         After administration of the initial calculated protamine dose following CPB, residual coagulopathy may be present in some cardiac surgical patients. (See
         <a class="medical medical_review" href="/z/d/html/122792.html" rel="external">
          "Achieving hemostasis after cardiac surgery with cardiopulmonary bypass", section on 'Achieving hemostasis and management of bleeding'
         </a>
         .)
        </p>
        <p>
         When persistent microvascular bleeding is observed after CPB, a small additional dose of protamine, typically 50 to 100 mg of protamine is often administered. This is reasonable if residual heparin is documented using a POC heparin-protamine titration assay, or suspected due to ACT values that are higher than baseline. In some cases, small amounts of heparin may be present due to reinfusion of heparinized blood from the CPB pump and/or release of heparin from poorly perfused colder peripheral tissues as rewarming occurs. However, each additional dose of protamine should be carefully considered, and protamine doses higher than 50 to 100 mg are avoided for the following reasons:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Any residual heparin concentration is usually minimal after administration of the initial dose of protamine, as described above (see
         <a class="local">
          'Initial protamine dosing strategies'
         </a>
         above). In fact, complete reversal of anticoagulation is usually achieved with a relatively low protamine-to-heparin ratio of approximately 0.5 to 0.8 mg/kg of protamine, with absence of blood levels of circulating heparin [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Persistent bleeding after CPB is common and usually due to factors other than the presence of residual heparin. These factors include inadequate surgical hemostasis, loss of platelets and coagulation factors due to high volume cell saver use, and effects of CPB including coagulopathy due to platelet activation (and consumption), hyperfibrinolysis induced by the extracorporeal circuit, hemodilution, and hypothermia. (See
         <a class="medical medical_review" href="/z/d/html/122792.html" rel="external">
          "Achieving hemostasis after cardiac surgery with cardiopulmonary bypass", section on 'Achieving hemostasis and management of bleeding'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Owing to its intrinsic anticoagulant effects, administration of excess protamine may actually prolong rather than shorten the ACT and result in exacerbation of bleeding and coagulopathy [
         <a href="#rid7">
          7,14-16,18
         </a>
         ]. One study in 487 cardiac surgical patients employed a dosing strategy with a protamine-to-heparin ratio of 0.8:1; however, additional 50 mg doses of protamine were administered empirically or if the ACT did not return to baseline levels [
         <a href="#rid19">
          19
         </a>
         ]. These investigators noted that higher doses of protamine were associated with increased risk of postoperative bleeding and transfusions.
         <em>
         </em>
         (See
         <a class="local">
          'Anticoagulant effects'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         Ideally, any additional doses of protamine are calculated using a heparin-protamine titration assay [
         <a href="#rid20">
          20-23
         </a>
         ]. Other tests that may help confirm residual heparin effect include checking ACT values and obtaining laboratory measurements of activated partial thromboplastin time (aPTT). (See
         <a class="medical medical_review" href="/z/d/html/112610.html" rel="external">
          "Intraoperative transfusion and administration of clotting factors", section on 'Tests of coagulation function'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H980354964">
         <span class="h3">
          Avoiding heparin rebound
         </span>
         <span class="headingEndMark">
          —
         </span>
         To prevent heparin rebound after initial protamine dosing, we administer a protamine infusion at 25 mg/hour, beginning after initial reversal of heparin anticoagulation and normalization of the ACT, and extending into the postoperative period over approximately four hours [
         <a href="#rid24">
          24-26
         </a>
         ].
        </p>
        <p>
         <em>
          Heparin rebound
         </em>
         is defined as evidence of reappearance of heparin with evidence on heparin-protamine titration assay, heparinase ACT, or additional laboratory data such as elevation of aPTT after initial protamine administration and documented normalization of the ACT. Rebound can occur regardless of the protamine dose administered to reverse heparin. Typically, heparin rebound occurs two to three hours after initial protamine dosing. Causes of rebound may include release of heparin previously bound in heparin-protamine complexes and possibly from poorly perfused tissues, vascular endothelium, or other stores [
         <a href="#rid4">
          4,24
         </a>
         ]. Rebound may also be more likely in patients who receive large doses of heparin to achieve initial anticoagulation for CPB due to altered heparin responsiveness (ie, “heparin resistance”) [
         <a href="#rid1">
          1,7
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/94297.html" rel="external">
          "Blood management and anticoagulation for cardiopulmonary bypass", section on 'Heparin resistance'
         </a>
         .)
        </p>
        <p>
         Although ACT values are routinely measured to document complete heparin reversal after protamine administration, this clot-based test is insensitive to low doses of heparin [
         <a href="#rid4">
          4-6
         </a>
         ]. Measurements of aPTT are also insensitive for detecting heparin levels in the low range of 0.1 to 0.3 international units/mL [
         <a href="#rid27">
          27,28
         </a>
         ]. Residual heparin effect in this range can potentially be measured using a POC heparin-protamine titration assay or heparinase ACT. However, even lower blood levels (ie, 0.05 up to 0.1 unit/mL) of heparin are not readily detectable with any of these tests but may still exert an anticoagulant effect.
        </p>
        <p>
         One trial randomized 300 cardiac surgical patients to receive a six-hour infusion of protamine at 25 mg/hour or a placebo beginning in the early postoperative period [
         <a href="#rid24">
          24
         </a>
         ]. Heparin rebound was noted in every patient in the placebo group between one and six hours after surgery, as reflected by increased thrombin clotting time and antifactor Xa activity, as well as by measurement of protein-bound heparin. However, rebound was not demonstrated in any patient in the protamine infusion group. Also, postoperative chest tube drainage was 13 percent less in patients receiving the protamine infusion [
         <a href="#rid24">
          24
         </a>
         ]. However, there were no differences in allogeneic blood transfusion between the two groups.
        </p>
        <p class="headingAnchor" id="H3403149782">
         <span class="h2">
          Use of protamine during other open or percutaneous cardiovascular procedures
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lower heparin doses are employed for open and percutaneous vascular surgical cases that do not involve the need for systemic anticoagulation for CPB. Thus, lower protamine doses are administered for heparin reversal in such cases, as discussed in separate topics:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Open abdominal aortic surgery
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/94260.html" rel="external">
          "Anesthesia for open abdominal aortic surgery", section on 'Anticoagulation management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Open thoracic aortic surgery
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/94266.html" rel="external">
          "Anesthesia for open descending thoracic aortic surgery", section on 'Point-of-care laboratory testing'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Carotid endarterectomy
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/90608.html" rel="external">
          "Anesthesia for carotid endarterectomy and carotid stenting", section on 'Anticoagulation during CEA'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Percutaneous endovascular aortic procedures
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/93506.html" rel="external">
          "Anesthesia for endovascular aortic repair", section on 'Management of anticoagulation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Percutaneous carotid artery stenting
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/90608.html" rel="external">
          "Anesthesia for carotid endarterectomy and carotid stenting", section on 'Anticoagulation during CAS or TCAR'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Electrophysiology suite
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/94294.html" rel="external">
          "Anesthetic considerations for electrophysiology procedures", section on 'Coagulation management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3005070712">
         <span class="h1">
          ADVERSE EFFECTS OF PROTAMINE: RECOGNITION AND MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H1026213680">
         <span class="h2">
          Protamine reactions: General considerations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Protamine reactions may occur rapidly, and it may not be possible to immediately determine the mechanism in an individual patient. Initial management is similar for each type of reaction, as described below.
        </p>
        <p>
         Adverse reactions may display a spectrum of signs and symptoms that include urticaria, bronchospasm, pulmonary hypertension with right ventricular (RV) failure, systemic hypotension, and/or shock [
         <a href="#rid29">
          29,30
         </a>
         ]. Reactions may be either nonimmunologic (eg, direct pharmacologic effects, mast cell degranulation/activation) or immunologic (eg, direct degranulation of mast cells, complement activation due to protamine-heparin complexes, or anaphylaxis due to IgE and/or IgG mediated responses) [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
         Severe life-threatening reactions are immediate hypersensitivity reactions and are not dose-dependent. However, determining whether milder adverse reactions are due to an immunologic response or direct effect of protamine such as vasodilation or myocardial depression can be challenging. Furthermore, if protamine is administered during cardiac surgery with cardiopulmonary bypass (CPB) or during another interventional cardiovascular procedure, cardiovascular complications unrelated to protamine administration, such as left or right ventricular dysfunction and/or arrhythmias, may contribute to development of hypotension and/or shock. In addition, identifying protamine as the culprit antigen for a suspected anaphylactic reaction is difficult if allogeneic blood products such as red blood cells, fresh frozen plasma (FFP), platelets, or cryoprecipitate were transfused concomitantly or shortly after protamine administration [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2325456876">
         <span class="h2">
          Vasodilation
         </span>
        </p>
        <p class="headingAnchor" id="H1937473901">
         <span class="h3">
          Clinical manifestations and mechanisms
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common adverse reaction to protamine is vasodilation. Although hypotension may develop, this is usually transient, not severe, and easily treated.
        </p>
        <p>
         Mechanisms for vasodilation may include complement activation due to protamine-heparin complexes. Following protamine administration, heparin binds to protamine as a simple acid-base interaction, forming a polyanionic-polycationic complex that binds and inactivates heparin. Furthermore, protamine has the potential for complement system activation by binding to C1 esterase and initiating classical complement pathway activation and the formation of C3a and C5a anaphylatoxins [
         <a href="#rid32">
          32
         </a>
         ]. Degranulation of connective tissue mast cells resulting in histamine release has also been implicated as a potential mechanism [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3878106470">
         <span class="h3">
          Management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although hypotension due to vasodilation is common (see
         <a class="local">
          'Vasodilation'
         </a>
         above), this is usually transient, not severe, and easily managed by administering vasopressors as necessary (
         <a class="graphic graphic_table graphicRef119747" href="/z/d/graphic/119747.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H3473233670">
         <span class="h2">
          Anaphylaxis and hypersensitivity reactions
         </span>
        </p>
        <p class="headingAnchor" id="H2171593344">
         <span class="h3">
          Clinical manifestations and mechanisms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple mechanisms are implicated in producing acute anaphylaxis and other acute hypersensitivity reactions to protamine [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
         Overt reactions generally occur within five minutes of protamine administration but may occur up to 20 minutes later [
         <a href="#rid30">
          30
         </a>
         ]. Signs range from local cutaneous responses such as urticaria, pulmonary responses including wheezing and bronchospasm, and cardiovascular responses including marked vasodilation with profound hypotension (also described as vasoplegia), and shock [
         <a href="#rid35">
          35,36
         </a>
         ]. Immediate hypersensitivity is IgE-mediated, causing mast cell and basophil activation with subsequent mediator release. In classic IgE mediated anaphylaxis, typical findings noted with transesophageal echocardiography (TEE) imaging in cardiac surgical patients include hypovolemia and hyperdynamic left ventricular (LV) function [
         <a href="#rid30">
          30
         </a>
         ]; however, some patients develop acute cardiopulmonary dysfunction and/or arrhythmias. (See
         <a class="medical medical_review" href="/z/d/html/2077.html" rel="external">
          "Perioperative anaphylaxis: Clinical manifestations, etiology, and management", section on 'Characteristic signs and symptoms'
         </a>
         .)
        </p>
        <p>
         Severe life-threatening anaphylactic reactions have been unpredictable [
         <a href="#rid37">
          37
         </a>
         ], suggesting that most are immunologically-induced IgE- or IgG-mediated responses. IgE is identified as the cause in 60 percent of severe anaphylactic reactions [
         <a href="#rid38">
          38,39
         </a>
         ], but other important pathophysiologic mechanisms include complement activation due to IgG formation [
         <a href="#rid30">
          30,40
         </a>
         ]. In particular, patients sensitized to protamine after previous exposure may form both IgE and specific IgG antibodies [
         <a href="#rid38">
          38
         </a>
         ]. Such IgG-mediated anaphylaxis has also been reported following reactions to proteins or volume expanders (dextrans) [
         <a href="#rid30">
          30
         </a>
         ]. In one study of 86 patients who had an anaphylactic reaction, IgG antibodies were found, as well as neutrophil activation and platelet activating factor levels that correlated with the severity of anaphylaxis [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
         Protamine-specific IgG antibodies may also activate complement activation, causing acute pulmonary vasoconstriction in some patients [
         <a href="#rid30">
          30
         </a>
         ]. (See
         <a class="local">
          'Acute (catastrophic) pulmonary vasoconstriction'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3733800126">
         <span class="h3">
          Management
         </span>
         <span class="headingEndMark">
          —
         </span>
         First-line treatment for suspected acute anaphylaxis includes stopping protamine and administration of epinephrine bolus(es) and infusion, as noted in the table (
         <a class="graphic graphic_table graphicRef107933" href="/z/d/graphic/107933.html" rel="external">
          table 2
         </a>
         ). Severe pulmonary responses may include wheezing and bronchospasm, while severe cardiovascular responses may include marked vasodilation with profound hypotension [
         <a href="#rid35">
          35,36
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2077.html" rel="external">
          "Perioperative anaphylaxis: Clinical manifestations, etiology, and management", section on 'Initial management'
         </a>
         .)
        </p>
        <p>
         For patients with refractory vasodilatory hypotension that does not respond to infusion of epinephrine, norepinephrine or vasopressin should be initiated (
         <a class="graphic graphic_table graphicRef119747" href="/z/d/graphic/119747.html" rel="external">
          table 1
         </a>
         ). Other agents such as
         <a class="drug drug_general" data-topicid="9636" href="/z/d/drug information/9636.html" rel="external">
          methylene blue
         </a>
         may also be administered for persistent severe vasodilation (
         <a class="graphic graphic_table graphicRef126194" href="/z/d/graphic/126194.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/115472.html" rel="external">
          "Intraoperative problems after cardiopulmonary bypass", section on 'Vasoplegia'
         </a>
         .)
        </p>
        <p>
         In some cardiac surgical cases, acute cardiovascular collapse may prompt readministering heparin to achieve systemic anticoagulation, reinserting arterial and venous cannulas (if these had been removed), and reinstituting CPB. Anti-inflammatory agents are administered after stabilizing the patient on CPB, if this was not done previously. Specifically, we treat for presumed anaphylaxis by administering a systemic steroid dose (eg,
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         125 mg), together with the H1 antihistamine
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         50 mg and an H2 receptor antagonist (eg,
         <a class="drug drug_general" data-topicid="8436" href="/z/d/drug information/8436.html" rel="external">
          famotidine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9265" href="/z/d/drug information/9265.html" rel="external">
          cimetidine
         </a>
         ), as noted in the table (
         <a class="graphic graphic_table graphicRef107933" href="/z/d/graphic/107933.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H3281430915">
         <span class="h2">
          Acute (catastrophic) pulmonary vasoconstriction
         </span>
        </p>
        <p class="headingAnchor" id="H1190176350">
         <span class="h3">
          Clinical manifestations and mechanisms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute pulmonary vasoconstriction with severe RV failure (also termed catastrophic pulmonary vasoconstriction) is an uncommon idiosyncratic life-threatening reaction that has been reported after protamine administration to reverse anticoagulation after CPB [
         <a href="#rid42">
          42
         </a>
         ]. Mean pulmonary artery pressure (PAP) may increase severalfold during acute pulmonary vasoconstriction. Since the RV is accustomed to ejecting against a relatively low mean PAP of approximately 15 mmHg, sudden increases in RV afterload cause acute RV dilatation, shifting the intraventricular septum into the LV cavity and further impeding ventricular loading. Shock develops rapidly.
        </p>
        <p>
         Catastrophic pulmonary vasoconstriction with RV failure is a rare hypersensitivity reaction that is probably complement-mediated due to antiprotamine IgG antibody interaction and/or protamine-heparin complex development, with C5a-mediated thromboxane formation [
         <a href="#rid30">
          30,43
         </a>
         ]. Pulmonary vasoconstriction occurs due to generation of the anaphylotoxin C5a, activation and aggregation of neutrophils that sequester in the pulmonary vasculature, microcirculatory occlusion, and thromboxane release [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2322228094">
         <span class="h3">
          Management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Similar to anaphylaxis, first-line treatment includes stopping protamine and administration of epinephrine bolus(es) and infusion, and other therapies as noted in the table (
         <a class="graphic graphic_table graphicRef107933" href="/z/d/graphic/107933.html" rel="external">
          table 2
         </a>
         ). In addition, inhaled pulmonary vasodilator agents may be administered. Patients who develop severe pulmonary vasoconstriction with RV failure and shock may require reinstitution of CPB, necessitating readministration of heparin to achieve systemic anticoagulation, as described above for cardiovascular collapse during anaphylaxis. (See
         <a class="local">
          'Management'
         </a>
         above and
         <a class="local">
          'Redosing protamine after a reaction'
         </a>
         below.)
        </p>
        <p>
         If acute pulmonary vasoconstriction with shock develops in an intensive care unit setting after protamine administration, then venoarterial (VA) extracorporeal membrane oxygenation (ECMO) is occasionally initiated as a life-saving strategy. (See
         <a class="medical medical_review" href="/z/d/html/134279.html" rel="external">
          "Extracorporeal life support in adults: Management of venoarterial extracorporeal membrane oxygenation (V-A ECMO)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2533527508">
         <span class="h2">
          Redosing protamine after a reaction
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are no clear guidelines regarding the safety of readministering protamine after a severe protamine reaction in patients who received additional heparin to achieve anticoagulation because of the need to reinstitute CPB. In most settings, readministration of the agent believed to cause anaphylaxis should be avoided. However, management of bleeding in a cardiac surgical patient who remains systemically anticoagulated is particularly challenging. Consultation among members of the anesthesiology, surgical, and perfusion teams is necessary to choose among the following options:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Some clinicians readminister protamine after weaning from CPB for the second time. There are reports of successful protamine administration in these settings [
         <a href="#rid44">
          44
         </a>
         ]. Theoretical reasons to explain why it is usually possible to readminister protamine without triggering another severe reaction in this setting include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Other causes of acute severe ventricular dysfunction are relatively common in cardiac surgical patients following weaning from CPB; thus, a hypersensitivity reaction to protamine may not have been the actual cause of cardiovascular collapse necessitating reinstitution of CPB.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The initial hypersensitivity reaction may lead to a refractory period with blunting of the response to a repeated exposure to the allergen, either due to inflammatory mediator depletion [
         <a href="#rid30">
          30,44
         </a>
         ] or acute consumption of IgG antibodies [
         <a href="#rid39">
          39,45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other clinicians avoid readministration of protamine, electing instead to reverse anticoagulation with use of blood products. In the absence of reversal, heparin has a half-life of approximately 60 to 90 minutes; thus, its anticoagulant effect may persist for four to six hours. Significant ongoing bleeding may occur during this period. Transfusion of large volumes of fresh frozen plasma (FFP), platelets, and fibrinogen, as well as red blood cells (RBCs) are typically necessary to control bleeding and coagulopathy until the anticoagulant effects of heparin are no longer clinically evident. Although large volume blood loss and replacement with blood products and/or volume expanders may result in dilution of the residual heparin concentration, massive blood transfusion has significant adverse clinical consequences [
         <a href="#rid44">
          44,46
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7931.html" rel="external">
          "Massive blood transfusion", section on 'Complications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Some patients remain unstable after redosing protamine after a second attempt to wean from CPB due to severe noncardiogenic pulmonary edema, acute lung injury, or cardiogenic shock. In such patients, temporary venoarterial (VA) or venovenous (VV) extracorporeal membrane oxygenation (ECMO) may rarely be employed after failed attempts to wean from CPB. (See
         <a class="medical medical_review" href="/z/d/html/115472.html" rel="external">
          "Intraoperative problems after cardiopulmonary bypass", section on 'Extracorporeal membrane oxygenation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H169451615">
         <span class="h2">
          Additional testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Notably, in any patient with a suspected anaphylactic reaction, a blood sample should be collected during or as soon as possible after the event for tryptase determination, which may be processed later. After postoperative recovery and hospital discharge, patients who had a severe reaction should be referred to an allergy specialist, as discussed in separate topics:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2077.html" rel="external">
          "Perioperative anaphylaxis: Clinical manifestations, etiology, and management", section on 'Laboratory tests at the time of the reaction'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2077.html" rel="external">
          "Perioperative anaphylaxis: Clinical manifestations, etiology, and management", section on 'Referral for allergy evaluation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3431452281">
         <span class="h2">
          Anticoagulant effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         As noted above, direct adverse anticoagulant effects can occur if excess protamine is administered. These include inhibition of coagulation factors and platelet function. These effects may increase risk for bleeding, with increases in activated clotting time (ACT) values [
         <a href="#rid3">
          3,4
         </a>
         ]. (See
         <a class="local">
          'Dosing for continued bleeding after initial protamine administration'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2182702405">
         <span class="h1">
          PREVENTION AND MITIGATION OF PROTAMINE REACTIONS
         </span>
        </p>
        <p class="headingAnchor" id="H3480172134">
         <span class="h2">
          Anticipating risk for protamine reactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         The general incidence of reactions to protamine in cardiac surgical patients is approximately 0.06 percent [
         <a href="#rid47">
          47
         </a>
         ]. Although there may be a slightly higher risk for a protamine reaction in the following groups of patients, screening for potential anti-protamine antibodies would not be clinically useful or practical and is not performed.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients taking protamine-containing insulin
         </strong>
         – Previous chronic use of protamine-containing insulin, particularly neutral protamine Hagedorn (NPH) insulin, is associated with increased risk for a protamine reaction. Repeated subcutaneous administration of NPH insulin induces anti-protamine IgE and/or anti-protamine IgG antibodies [
         <a href="#rid38">
          38
         </a>
         ]. The incidence of anaphylaxis after protamine administration in cardiac surgical patients using NPH insulin is in the range of 0.6 to 2 percent, while the incidence of reactions in other cardiac surgical patients is approximately 0.06 percent [
         <a href="#rid47">
          47,48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although patients receiving protamine-containing insulins may be at slightly increased risk, screening such patients for potential anti-protamine antibodies is not currently performed because:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Risk is relatively low even in those who have taken NPH insulin, and NPH insulin is used less commonly than in the past.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         There are no clinically available tests for the IgE and IgG antibodies that are likely responsible for most hypersensitivity reactions to protamine.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         There are no alternative heparin reversal agents.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients who have had a vasectomy
         </strong>
         –
         <strong>
         </strong>
         Prior vasectomy is associated with increased risk for a protamine reaction because of development of autoantibodies to the patient’s own sperm [
         <a href="#rid49">
          49
         </a>
         ]. Testes are immunologically isolated, but following vasectomy, the immune system develops antibodies to human sperm. Case reports postulate that the antisperm antibodies can also cross-react with protamine, potentially causing hypersensitivity reactions since protamine is derived from salmon testes [
         <a href="#rid29">
          29,49
         </a>
         ]. However, in a prospective study that included 16 patients with a prior vasectomy before cardiac surgery, none developed an adverse reaction following protamine administration [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with shellfish or other fish allergies
         </strong>
         –
         <strong>
         </strong>
         Patients with a history of multiple drug or food allergies, particularly shellfish or fish allergies, may be at risk for hypersensitivity to various agents administered in a surgical setting. Limited evidence confined to case reports suggests that a history of fish allergy may be associated with increased risk for a protamine reaction [
         <a href="#rid29">
          29,30
         </a>
         ]. However, this risk is low since humans consume fish muscle tissue, while protamine is produced from the milt (testes) of salmon. In one prospective study, six patients undergoing cardiac surgery had a history of fish allergy; none of these developed an adverse reaction following protamine administration [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H905028355">
         <span class="h2">
          Administering a test dose
         </span>
         <span class="headingEndMark">
          —
         </span>
         We typically administer a test dose of protamine (ie, a small dose of 5 to 10 mg) initially, with a brief pause before administration of the remainder of the full therapeutic dose.
        </p>
        <p>
         A test doses provides the first antigenic exposure of a patient to an agent. However, even a test dose may produce an anaphylactic reaction, or a reaction may still occur after a negative response to a test dose [
         <a href="#rid30">
          30
         </a>
         ]. For these reasons, the clinician should always be prepared to treat any reaction before administering any protamine. (See
         <a class="local">
          'Adverse effects of protamine: Recognition and management'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1519592016">
         <span class="h2">
          Other efforts
         </span>
        </p>
        <p class="headingAnchor" id="H3404399083">
         <span class="h3">
          Using a slow infusion rate
         </span>
         <span class="headingEndMark">
          —
         </span>
         After administration of the test dose, the remainder of the full therapeutic protamine dose is administered while taking care to avoid rapid IV push to maintain hemodynamic stability [
         <a href="#rid4">
          4,33
         </a>
         ]. (See
         <a class="local">
          'Protamine reversal of heparin anticoagulaton: Uses and dosing strategies'
         </a>
         above.)
        </p>
        <p>
         Although prescribing information suggests that “
         <a class="drug drug_general" data-topicid="9831" href="/z/d/drug information/9831.html" rel="external">
          protamine sulfate
         </a>
         injection should be given by very slow intravenous (IV) injection over a 10-minute period in doses not to exceed 50 mg” [
         <a href="#rid50">
          50
         </a>
         ], this very slow rate of administration is impractical in clinical settings like cardiac surgery that require large doses of protamine [
         <a href="#rid4">
          4,51
         </a>
         ]. For example, expeditious reversal of systemic anticoagulation is necessary after weaning from CPB so that bleeding can be controlled. Since typical protamine doses are 200 to 300 mg in cardiac surgical settings (see
         <a class="local">
          'Protamine administration after cardiopulmonary bypass'
         </a>
         above), a suggested rate of administration of only 50 mg every 10 minutes would require approximately 60 minutes for full reversal of anticoagulation, resulting in adverse consequences that include significant bleeding and need for transfusion during the post-bypass period.
        </p>
        <p class="headingAnchor" id="H3468764247">
         <span class="h3">
          Timing of administration
         </span>
         <span class="headingEndMark">
          —
         </span>
         Administration of protamine is accomplished shortly after weaning from cardiopulmonary bypass (CPB). Some surgeons avoid protamine prior to aortic decannulation to avoid risk of thrombus formation at the tip of the cannula, while others prefer to administer some of the initial protamine dose before removing the aortic cannula to facilitate an immediate return to CPB in the event of a severe reaction to protamine. (See
         <a class="local">
          'Anaphylaxis and hypersensitivity reactions'
         </a>
         above and
         <a class="local">
          'Acute (catastrophic) pulmonary vasoconstriction'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H388466597">
         <span class="h3">
          Choosing the site of administration
         </span>
         <span class="headingEndMark">
          —
         </span>
         Protamine can be administered either via a peripheral IV catheter or a central venous catheter. Since severe reactions are due to immunologic responses to preexisting antibodies, using a peripheral IV route of administration is not an effective preventive measure [
         <a href="#rid30">
          30
         </a>
         ]. We avoid other alternative routes of protamine injection such as left atrial or intra-aortic protamine infusion that have been suggested to bypass the lungs. Concerns regarding these alternative routes include increased likelihood of inducing hemodynamic instability, as well as risk for cerebral or coronary embolism of injected air or particles formed by protamine-heparin complexes [
         <a href="#rid52">
          52,53
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3082165186">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration of protamine after cardiopulmonary bypass (CPB)
         </strong>
         – During cardiac surgical procedures, systemic anticoagulation with
         <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">
          unfractionated heparin
         </a>
         (UFH) is monitored throughout cardiopulmonary bypass (CPB) using a point-of-care (POC) contact activation test of the effects of heparin (the activated clotting time [ACT]). After weaning from CPB, protamine is administered intravenously (IV) for rapid reversal of heparin anticoagulation. There are no alternative agents to reverse UFH. (See
         <a class="local">
          'General considerations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Initial intraoperative dosing
         </strong>
         – We suggest calculating the protamine dose based on a POC titration assay to existing heparin in the blood, if available (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). A reasonable alternative is an empiric protamine dosing strategy with administration of 0.8 mg protamine per 100 units of the initial prebypass heparin dose with use of ACT monitoring. (See
         <a class="local">
          'Titration based on point-of-care heparin assays'
         </a>
         above and
         <a class="local">
          'Empiric dosing strategies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Dosing for continued intraoperative bleeding
         </strong>
         – If residual heparin effect is suspected due to persistent microvascular bleeding and/or ACT values that are higher than baseline, we suggest administering an additional protamine dose according to POC assay measurements of residual heparin, or a dose of 25 to 50 mg if this assay is not available (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
         <strong>
         </strong>
         We avoid excess protamine to avoid its anticoagulant effects.
         <em>
         </em>
         (See
         <a class="local">
          'Dosing for continued bleeding after initial protamine administration'
         </a>
         above and
         <a class="local">
          'Anticoagulant effects'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Avoiding heparin rebound
         </strong>
         – We suggest also administering a protamine infusion at 25 to 50 mg/hour to avoid "heparin rebound,” beginning later in the intraoperative period and continuing for four to six postoperative hours (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Avoiding heparin rebound'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Recognition and management of protamine reactions
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Vasodilation
         </strong>
         – The most common adverse reaction to protamine is vasodilation. Although hypotension may develop, this is usually transient, not severe, and easily managed by administering vasopressors as necessary (
         <a class="graphic graphic_table graphicRef119747" href="/z/d/graphic/119747.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Vasodilation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Anaphylaxis
         </strong>
         – A more severe anaphylactic is less common and unpredictable. Treatment includes stopping protamine administration, and administration of epinephrine and other therapies as described in the table (
         <a class="graphic graphic_table graphicRef107933" href="/z/d/graphic/107933.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Anaphylaxis and hypersensitivity reactions'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2077.html" rel="external">
          "Perioperative anaphylaxis: Clinical manifestations, etiology, and management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Acute pulmonary vasoconstriction
         </strong>
         – Acute pulmonary vasoconstriction leading to right ventricular failure is a rare and catastrophic reaction. First-line treatment is similar to that for anaphylaxis (
         <a class="graphic graphic_table graphicRef107933" href="/z/d/graphic/107933.html" rel="external">
          table 2
         </a>
         ). In most cases, readministration of heparin to achieve systemic anticoagulation and reinstitution of CPB is necessary. (See
         <a class="local">
          'Acute (catastrophic) pulmonary vasoconstriction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Redosing protamine after a reaction
         </strong>
         – For patients who received additional heparin to achieve systemic anticoagulation for reinstitution of CPB after a severe protamine reaction (see
         <a class="local">
          'Redosing protamine after a reaction'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Some clinicians cautiously readminister protamine as usual, since a severe second reaction is rare.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Other clinicians avoid readministration of protamine, instead reversing anticoagulation by administering blood products.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Rarely, temporary extracorporeal membrane oxygenation (ECMO) is considered in a patient with severe noncardiogenic pulmonary edema, acute lung injury, or cardiogenic shock after failed attempts to wean from CPB.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention and mitigation of protamine reactions and other adverse effects
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Anticipating higher risk
         </strong>
         – Despite the possibility of very slightly higher risk for a protamine reaction in patients receiving neutral protamine Hagedorn (NPH) insulin, and in those with known fish allergies or prior vasectomy, screening for potential anti-protamine antibodies would not be clinically useful or practical and is not performed. (See
         <a class="local">
          'Anticipating risk for protamine reactions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Administering a test dose
         </strong>
         – A "test dose" of protamine 5 to 10 mg is administered to possibly allow early detection of a severe protamine reaction; the remaining dose is administered after approximately five minutes later. (See
         <a class="local">
          'Administering a test dose'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Other efforts
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         After the test dose, the remainder of the full therapeutic protamine dose is administered while taking care to avoid rapid IV push to maintain hemodynamic stability. (See
         <a class="local">
          'Using a slow infusion rate'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Many surgeons avoid protamine prior to aortic decannulation to avoid risk of thrombus formation; however, some surgeons administer part of the dose before removing the aortic cannula to facilitate immediate return to CPB. (See
         <a class="local">
          'Timing of administration'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Either a peripheral IV catheter or a central venous catheter may be used. (See
         <a class="local">
          'Choosing the site of administration'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Butterworth J, Lin YA, Prielipp RC, et al. Rapid disappearance of protamine in adults undergoing cardiac operation with cardiopulmonary bypass. Ann Thorac Surg 2002; 74:1589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maier CL, Sniecinski RM. Anticoagulation Monitoring for Perioperative Physicians. Anesthesiology 2021; 135:738.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Despotis GJ, Joist JH, Hogue CW Jr, et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 1995; 110:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Despotis GJ, Gravlee G, Filos K, Levy J. Anticoagulation monitoring during cardiac surgery: a review of current and emerging techniques. Anesthesiology 1999; 91:1122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levy JH, Montes F, Szlam F, Hillyer CD. The in vitro effects of antithrombin III on the activated coagulation time in patients on heparin therapy. Anesth Analg 2000; 90:1076.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Despotis GJ, Joist JH, Hogue CW Jr, et al. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemost 1996; 76:902.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shore-Lesserson L, Baker RA, Ferraris VA, et al. The Society of Thoracic Surgeons, The Society of Cardiovascular Anesthesiologists, and The American Society of ExtraCorporeal Technology: Clinical Practice Guidelines-Anticoagulation During Cardiopulmonary Bypass. Ann Thorac Surg 2018; 105:650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raphael J, Mazer CD, Subramani S, et al. Society of Cardiovascular Anesthesiologists Clinical Practice Improvement Advisory for Management of Perioperative Bleeding and Hemostasis in Cardiac Surgery Patients. Anesth Analg 2019; 129:1209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tibi P, McClure RS, Huang J, et al. STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management. Ann Thorac Surg 2021; 112:981.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mueller MM, Van Remoortel H, Meybohm P, et al. Patient Blood Management: Recommendations From the 2018 Frankfurt Consensus Conference. JAMA 2019; 321:983.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Curry NS, Davenport R, Pavord S, et al. The use of viscoelastic haemostatic assays in the management of major bleeding: A British Society for Haematology Guideline. Br J Haematol 2018; 182:789.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kozek-Langenecker SA, Ahmed AB, Afshari A, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology: First update 2016. Eur J Anaesthesiol 2017; 34:332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang J, Ma HP, Zheng H. Blood loss after cardiopulmonary bypass, standard vs titrated protamine: a meta-analysis. Neth J Med 2013; 71:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mochizuki T, Olson PJ, Szlam F, et al. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Anesth Analg 1998; 87:781.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meesters MI, Veerhoek D, de Jong JR, Boer C. A Pharmacokinetic Model for Protamine Dosing After Cardiopulmonary Bypass. J Cardiothorac Vasc Anesth 2016; 30:1190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boer C, Meesters MI, Veerhoek D, Vonk ABA. Anticoagulant and side-effects of protamine in cardiac surgery: a narrative review. Br J Anaesth 2018; 120:914.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kjellberg G, Sartipy U, van der Linden J, et al. An Adjusted Calculation Model Allows for Reduced Protamine Doses without Increasing Blood Loss in Cardiac Surgery. Thorac Cardiovasc Surg 2016; 64:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wahba A, Milojevic M, Boer C, et al. 2019 EACTS/EACTA/EBCP guidelines on cardiopulmonary bypass in adult cardiac surgery. Eur J Cardiothorac Surg 2020; 57:210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Despotis GJ, Filos KS, Zoys TN, et al. Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: a multivariate analysis in cardiac surgical patients. Anesth Analg 1996; 82:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abuelkasem E, Mazzeffi MA, Henderson RA, et al. Clinical Impact of Protamine Titration-Based Heparin Neutralization in Patients Undergoing Coronary Bypass Grafting Surgery. J Cardiothorac Vasc Anesth 2019; 33:2153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guo Y, Tang J, Du L, et al. Protamine dosage based on two titrations reduces blood loss after valve replacement surgery: a prospective, double-blinded, randomized study. Can J Cardiol 2012; 28:547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vonk AB, Veerhoek D, van den Brom CE, et al. Individualized heparin and protamine management improves rotational thromboelastometric parameters and postoperative hemostasis in valve surgery. J Cardiothorac Vasc Anesth 2014; 28:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koster A, Börgermann J, Gummert J, et al. Protamine overdose and its impact on coagulation, bleeding, and transfusions after cardiopulmonary bypass: results of a randomized double-blind controlled pilot study. Clin Appl Thromb Hemost 2014; 20:290.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teoh KH, Young E, Blackall MH, et al. Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery? J Thorac Cardiovasc Surg 2004; 128:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jia Z, Tian G, Ren Y, et al. Pharmacokinetic model of unfractionated heparin during and after cardiopulmonary bypass in cardiac surgery. J Transl Med 2015; 13:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stone ME, Vespe MW. Heparin Rebound: An In-Depth Review. J Cardiothorac Vasc Anesth 2023; 37:601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galeone A, Rotunno C, Guida P, et al. Monitoring incomplete heparin reversal and heparin rebound after cardiac surgery. J Cardiothorac Vasc Anesth 2013; 27:853.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taneja R, Marwaha G, Sinha P, et al. Elevated activated partial thromboplastin time does not correlate with heparin rebound following cardiac surgery. Can J Anaesth 2009; 56:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levy JH, Piccini JP. Protamine reversal of heparin: a fishy practice? Europace 2019; 21:840.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levy JH, Adkinson NF Jr. Anaphylaxis during cardiac surgery: implications for clinicians. Anesth Analg 2008; 106:392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tacquard C, Iba T, Levy JH. Perioperative Anaphylaxis. Anesthesiology 2023; 138:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rent R, Ertel N, Eisenstein R, Gewurz H. Complement activation by interaction of polyanions and polycations. I. Heparin-protamine induced consumption of complement. J Immunol 1975; 114:120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sauder RA, Hirshman CA. Protamine-induced histamine release in human skin mast cells. Anesthesiology 1990; 73:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sampson HA, Muñoz-Furlong A, Bock SA, et al. Symposium on the definition and management of anaphylaxis: summary report. J Allergy Clin Immunol 2005; 115:584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pumphrey RS. Lessons for management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy 2000; 30:1144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pumphrey RS, Roberts IS. Postmortem findings after fatal anaphylactic reactions. J Clin Pathol 2000; 53:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morel DR, Zapol WM, Thomas SJ, et al. C5a and thromboxane generation associated with pulmonary vaso- and broncho-constriction during protamine reversal of heparin. Anesthesiology 1987; 66:597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiss ME, Nyhan D, Peng ZK, et al. Association of protamine IgE and IgG antibodies with life-threatening reactions to intravenous protamine. N Engl J Med 1989; 320:886.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiss ME, Adkinson NF Jr. Allergy to protamine. Clin Rev Allergy 1991; 9:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reber LL, Hernandez JD, Galli SJ. The pathophysiology of anaphylaxis. J Allergy Clin Immunol 2017; 140:335.
          </a>
         </li>
         <li class="breakAll">
          Jonsson F, de Chaisemartin L, Granger V, et al. An IgG-induced neutrophil activation pathway contributes to human drug-induced anaphylaxis. Sci Transl Med 2019;11(500).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lowenstein E, Johnston WE, Lappas DG, et al. Catastrophic pulmonary vasoconstriction associated with protamine reversal of heparin. Anesthesiology 1983; 59:470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lowenstein E, Zapol WM. Protamine reactions, explosive mediator release, and pulmonary vasoconstriction. Anesthesiology 1990; 73:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valchanov K, Falter F, George S, et al. Three Cases of Anaphylaxis to Protamine: Management of Anticoagulation Reversal. J Cardiothorac Vasc Anesth 2019; 33:482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiss ME, Chatham F, Kagey-Sobotka A, Adkinson NF Jr. Serial immunological investigations in a patient who had a life-threatening reaction to intravenous protamine. Clin Exp Allergy 1990; 20:713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turan A, Yang D, Bonilla A, et al. Morbidity and mortality after massive transfusion in patients undergoing non-cardiac surgery. Can J Anaesth 2013; 60:761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levy JH, Schwieger IM, Zaidan JR, et al. Evaluation of patients at risk for protamine reactions. J Thorac Cardiovasc Surg 1989; 98:200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levy JH, Zaidan JR, Faraj B. Prospective evaluation of risk of protamine reactions in patients with NPH insulin-dependent diabetes. Anesth Analg 1986; 65:739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samuel T. Antibodies reacting with salmon and human protamines in sera from infertile men and from vasectomized men and monkeys. Clin Exp Immunol 1977; 30:181.
          </a>
         </li>
         <li class="breakAll">
          PROTAMINE SULFATE- protamine sulfate injection, solution https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94d4f57f-940e-c0a8-e053-2a95a90ae3af&amp;type=display (Accessed on January 31, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wakefield TW, Hantler CB, Wrobleski SK, et al. Effects of differing rates of protamine reversal of heparin anticoagulation. Surgery 1996; 119:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milne B, Rogers K, Cervenko F, Salerno T. The haemodynamic effects of intraaortic versus intravenous administration of protamine for reversal of heparin in man. Can Anaesth Soc J 1983; 30:347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kronenfeld MA, Garguilo R, Weinberg P, et al. Left atrial injection of protamine does not reliably prevent pulmonary hypertension. Anesthesiology 1987; 67:578.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 140293 Version 5.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12440613" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Rapid disappearance of protamine in adults undergoing cardiac operation with cardiopulmonary bypass.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34499103" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Anticoagulation Monitoring for Perioperative Physicians.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7609568" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10519514" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Anticoagulation monitoring during cardiac surgery: a review of current and emerging techniques.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10781455" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The in vitro effects of antithrombin III on the activated coagulation time in patients on heparin therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8972009" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29362176" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The Society of Thoracic Surgeons, The Society of Cardiovascular Anesthesiologists, and The American Society of ExtraCorporeal Technology: Clinical Practice Guidelines-Anticoagulation During Cardiopulmonary Bypass.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31613811" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Society of Cardiovascular Anesthesiologists Clinical Practice Improvement Advisory for Management of Perioperative Bleeding and Hemostasis in Cardiac Surgery Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34217505" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30860564" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Patient Blood Management: Recommendations From the 2018 Frankfurt Consensus Conference.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30073664" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The use of viscoelastic haemostatic assays in the management of major bleeding: A British Society for Haematology Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28459785" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology: First update 2016.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23712807" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Blood loss after cardiopulmonary bypass, standard vs titrated protamine: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9768770" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27493093" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : A Pharmacokinetic Model for Protamine Dosing After Cardiopulmonary Bypass.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29661409" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Anticoagulant and side-effects of protamine in cardiac surgery: a narrative review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26270199" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : An Adjusted Calculation Model Allows for Reduced Protamine Doses without Increasing Blood Loss in Cardiac Surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31576396" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : 2019 EACTS/EACTA/EBCP guidelines on cardiopulmonary bypass in adult cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8712388" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: a multivariate analysis in cardiac surgical patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30737123" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Clinical Impact of Protamine Titration-Based Heparin Neutralization in Patients Undergoing Coronary Bypass Grafting Surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22633184" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Protamine dosage based on two titrations reduces blood loss after valve replacement surgery: a prospective, double-blinded, randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24342152" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Individualized heparin and protamine management improves rotational thromboelastometric parameters and postoperative hemostasis in valve surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23564056" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Protamine overdose and its impact on coagulation, bleeding, and transfusions after cardiopulmonary bypass: results of a randomized double-blind controlled pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15282457" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25638272" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Pharmacokinetic model of unfractionated heparin during and after cardiopulmonary bypass in cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36641308" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Heparin Rebound: An In-Depth Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23627997" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Monitoring incomplete heparin reversal and heparin rebound after cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19408066" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Elevated activated partial thromboplastin time does not correlate with heparin rebound following cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30689823" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Protamine reversal of heparin: a fishy practice?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18227290" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Anaphylaxis during cardiac surgery: implications for clinicians.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36413685" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Perioperative Anaphylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/234494" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Complement activation by interaction of polyanions and polycations. I. Heparin-protamine induced consumption of complement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1694414" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Protamine-induced histamine release in human skin mast cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15753908" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Symposium on the definition and management of anaphylaxis: summary report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10931122" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Lessons for management of anaphylaxis from a study of fatal reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10823122" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Postmortem findings after fatal anaphylactic reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3495208" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : C5a and thromboxane generation associated with pulmonary vaso- and broncho-constriction during protamine reversal of heparin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2648147" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Association of protamine IgE and IgG antibodies with life-threatening reactions to intravenous protamine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1782626" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Allergy to protamine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28780941" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : The pathophysiology of anaphylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28780941" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : The pathophysiology of anaphylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6638558" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Catastrophic pulmonary vasoconstriction associated with protamine reversal of heparin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2393123" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Protamine reactions, explosive mediator release, and pulmonary vasoconstriction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29678436" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Three Cases of Anaphylaxis to Protamine: Management of Anticoagulation Reversal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1707334" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Serial immunological investigations in a patient who had a life-threatening reaction to intravenous protamine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23609882" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Morbidity and mortality after massive transfusion in patients undergoing non-cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2755152" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Evaluation of patients at risk for protamine reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2424341" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Prospective evaluation of risk of protamine reactions in patients with NPH insulin-dependent diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/414865" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Antibodies reacting with salmon and human protamines in sera from infertile men and from vasectomized men and monkeys.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/414865" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Antibodies reacting with salmon and human protamines in sera from infertile men and from vasectomized men and monkeys.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8571194" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Effects of differing rates of protamine reversal of heparin anticoagulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6871776" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : The haemodynamic effects of intraaortic versus intravenous administration of protamine for reversal of heparin in man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3662086" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Left atrial injection of protamine does not reliably prevent pulmonary hypertension.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
